Hormonal
Precision nutrition strategies, including monitoring postprandial glycemic responses and gut microbiome composition, may attenuate unfavorable cardiovascular risk factors associated with menopause.
Consider how your body responds to specific foods after eating (postprandial response). While full precision nutrition testing may not be available, focusing on fiber, reducing sugar, and potentially incorporating isoflavone-rich foods (like soy) may support gut health and metabolic stability during menopause.
Data from a large-scale investigation of the menopause transition suggests nutritional strategies that address postprandial glycemic responses, and the gut microbiome may attenuate some of the unfavorable effects of menopause on CVD risk factors.
Why this rating
Based on observational data from PREDICT-1 and narrative reviews; RCTs specifically for precision nutrition in menopause are lacking.
Source
Precision Nutrition for Management of Cardiovascular Disease Risk During Menopause
Hannah E. Cabre et al. · Lifestyle Genomics · 2024
DOI 10.1159/000540337
More from this paper
- Adherence to the Mediterranean Diet (MED) or Dietary Approaches to Stop Hypertension (DASH) improves cardiovascular disease risk biomarkers (total and LDL cholesterol, blood pressure) and reduces oxidative stress and inflammation in postmenopausal women.Moderate
- Genotype-matched dietary interventions (low-fat vs. low-carbohydrate) may not consistently predict weight loss success in postmenopausal women compared to general overweight populations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →